切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2017, Vol. 05 ›› Issue (03) : 156 -159. doi: 10.3877/cma.j.issn.2095-5820.2017.03.007

所属专题: 专题评论 文献

质量控制

内分泌项目性能评价中的标准化西格玛性能验证图应用
李国柱1, 张剑宏1, 关坤萍1, 朱爱萍1, 郭存九1,()   
  1. 1. 030001 太原,山西医科大学第二医院检验科
  • 收稿日期:2017-06-28 出版日期:2017-08-28
  • 通信作者: 郭存九

Application of standardized Sigma performance verification diagram in performance evaluation of endocrine testing

Guozhu Li1, Jianhong Zhang1, Kunping Guan1, Aiping Zhu1, Cunjiu Guo1,()   

  1. 1. Clinical laboratory, Second Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2017-06-28 Published:2017-08-28
  • Corresponding author: Cunjiu Guo
  • About author:
    Corresponding author: Guo Cunjiu, Email:
引用本文:

李国柱, 张剑宏, 关坤萍, 朱爱萍, 郭存九. 内分泌项目性能评价中的标准化西格玛性能验证图应用[J/OL]. 中华临床实验室管理电子杂志, 2017, 05(03): 156-159.

Guozhu Li, Jianhong Zhang, Kunping Guan, Aiping Zhu, Cunjiu Guo. Application of standardized Sigma performance verification diagram in performance evaluation of endocrine testing[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2017, 05(03): 156-159.

目的

应用西格玛(sigma,σ)性能验证对内分泌项目进行性能评价,结合质量目标指数(quality goal index,QGI)查找导致部分项目性能不佳的原因,为提升内分泌项目的质量提供整改方向。

方法

选取山西医科大学第二医院实验室参加2016年卫计委临床检验中心内分泌室间质量评价(external quality assessment,EQA)的9个项目作为评价对象,将实验室高低两个水平室内质控累积在控变异系数(coefficient of variation,CV)分别作为估计值,内分泌EQA的百分差值作为实验室的偏倚估计,采用卫生部室间质评标准内分泌项目可接受范围作为允许总误差(total error allowance,TEa),计算各内分泌项目的性能评价指标σ值和QGI。根据σ水平统计9项内分泌项目的σ值分布情况,评价质量水平。统计<6σ水平的内分泌项目的QGI分布情况,分析各项目需要采取的改进措施。

结果

低水平室内质控:4≤σ<5的项目睾酮(testosterone,T)、叶酸(Folate),占22.22%;3≤σ<4的项目游离甲状腺素(free thyroxine,FT4)、促卵泡生成激素(follicle stimulating hormone,FSH)、黄体生成素(luteinizing hormone,LH)、维生素B12(vitamin B12,VitB12),占44.44%;σ<3的项目游离三碘甲状腺原氨酸(free triiodothyronine,FT3)、促甲状腺激素(thyroid stimulating hormone,TSH)、孕酮(progesterone,Prog),占33.33%。高水平室内质控:σ≥6的项目T,占11.11%;5≤σ<6 的项目Folate,占11.11%;4≤σ<5的项目LH,占11.11%;3≤σ<4的项目FT3、FT4、FSH、Prog、VitB12,占55.56%;σ<3的项目TSH,占11.11%。在<6σ水平的内分泌项目中,QGI<0.8的项目有FT3、FT4、FSH、LH、Prog、Folate、VitB12;QGI>1.2的项目有TSH、T。故需改进精密度的项目有FT3、FT4、FSH、LH、Prog、Folate、VitB12;需改进正确度的项目TSH、T。

结论

西格玛性能验证可对实验室检测的9项内分泌项目的性能进行较为客观评价,结合QGI可查找项目性能不佳的原因,为实验室质量改进作出指导。

Objective

To evaluate the analytical performance of endocrine testing using six sigma(σ), and find the cause of dissatisfied performance for some projects combined with the quality goal index (QGI), so that provide rectification direction for the improvement of the endocrine projects quality.

Methods

Nine endocrine items which participated in the clinical laboratory external quality assessment (EQA) of the Ministry of Health in 2016 was selected in this study. The two levels of laboratory internal quality control were accumulated in coefficient fo varivation (CV), respectively, as the estimation value. By adopting the quality evaluation standard of the Ministy of public healty the acceptable range of endocrine items was measured as the total allowah error (TEa). CV and Bias with the data of internal quality control (IQC) and EQA was evaluated. The sigma metrics based on the TEa from the National Center for Clinical Laboratory were in accord with the formula σ=(TEa-|Bias|)/CV for each endocrine test. Quality goal index(QGI) was also calculated to investigate the reason for dissatisfied performance as follows: QGI=Bias/(1.5*CV). Evaluate the quality levels of nine endocrine tests with σstatistics. Analyze which improvement measures were needed for each project with QGI.

Results

In low level of IQC, the rates of endocrine items for 4≤σ<5σ, 3≤σ<4, σ<3 were 22.22%, 44.44%, 33.33%, respectively. In high level IQC, the rates of endocrine items for σ≥6, 5≤σ<6, 4≤σ<5, 3≤σ<4, σ<3 were 11.11%, 11.11%, 11.11%, 55.56% and 11.11%, respectively. In the dissatisfied performance of the endocrine tests, which the QGI<0.8 include FT3, FT4, FSH, LH, Prog, Folate, VitB12, which the QGI>1.2 include TSH, T.

Conclusions

Sigma performance verification can be used to evaluate the performance of laboratory testing projects. The sigma and QGI can be used for investigation of the reason for dissatisfied perfarmance of the project, and guiding the improvement of clinical laboratory quality.

表1 9项内分泌项目以不同水平室内质控计算σ及QGI结果
表2 各内分泌项目高、低水平σ值分布情况
图1 室内质控低水平(a)与高水平(b)标准化西格玛性能验证图
表3 σ<6内分泌项目QGI分布情况
1
Nevalainen D, Berte L, Kraft C, et al. Evaluating laboratory performance on quality indicators with the six sigma scale[J]. Arch Pathol Lab Med, 2000,124(4):516-519.
2
Chassin MR. Is health care ready for Six Sigma quality [J]. Milbank Q, 1998,76(4):565-591, 510.
3
Topic E, Nikolac N, Panteghini M, et al. How to assess the quality of your analytical method[J]. Clin Chem Lab Med, 2015,53(11):1707-1718.
4
肖亚玲,王 薇,赵海建,等. 西格玛性能验证图在常规化学检测项目性能评价中的应用[J]. 现代检验医学杂志, 2016,31(4):159-162.
5
Kang F, Zhang C, Wang W, et al. Sigma metric analysis for performance of creatinine with fresh frozen serum[J]. Scand J Clin Lab Invest, 2016,76(1):40-44.
6
肖亚玲,王薇,王治国. 心肌损伤标志物四项检测性能的西格玛水平分析[J]. 现代检验医学杂志, 2014,29(1):38-41.
7
王治国. 临床检验6σ质量设计与控制[M]. 北京:人民卫生出版社, 2012.
8
王治国. 临床检验方法确认与性能验证[M]. 北京:人民卫生出版社, 2012.
9
赵海建,张传宝,周伟燕,等. 应用六西格玛管理方法评价脂类检验项目质量水平[J]. 中华检验医学杂志, 2014,37(4):311-314.
10
靳冰,赵强元,刘敏,等. 应用六西格玛管理方法评价实验室质量水平[J]. 国际检验医学杂志, 2015,36(6):743-744.
[1] 古娇娇, 李文涛. SHP基因影响乳腺癌内分泌治疗耐药的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(02): 124-127.
[2] 穆星豆, 姜月, 张聚良. 细胞周期蛋白依赖性激酶4/6抑制剂在乳腺癌内分泌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(01): 47-51.
[3] 向韵, 卢游, 杨凡. 全氟及多氟烷基化合物暴露与儿童肥胖症相关性研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 569-574.
[4] 蔡大明, 陆晓峰, 王行舟, 王萌, 刘颂, 夏雪峰, 沈晓菲, 杜峻峰, 管文贤. 三级淋巴结构在胃神经内分泌瘤中的预后价值及预后预测模型构建[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 401-405.
[5] 胡思平, 熊性宇, 徐航, 杨璐. 衰老相关分泌表型因子在前列腺癌发生发展中的作用机制[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 425-434.
[6] 赖圣杰, 方欣, 方友强. 2023年欧洲内分泌学会及加拿大泌尿外科学会肾上腺偶发瘤诊疗指南解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 309-312.
[7] 谭智勇, 付什, 李宁, 王海峰, 王剑松. 膀胱小细胞癌发病机制及其诊疗研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 183-187.
[8] 王妍, 李征, 卓奇峰, 周陈杰, 吉顺荣, 徐晓武, 陈洁, 虞先濬. 微小无功能性胰腺神经内分泌瘤外科治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 607-614.
[9] 翁桂湖, 刘悦泽, 张太平. 胰腺神经内分泌肿瘤治疗进展与争议[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 602-606.
[10] 陆思楠, 苏同荣, 张启逸. 索凡替尼转化治疗胰腺神经内分泌肿瘤肝转移一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 526-530.
[11] 杨秀君, 崔梦莹, 刘水, 盛基尧, 张丹. 基于SEER数据库胰头部胰腺神经内分泌癌患者预后列线图构建与验证[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 520-525.
[12] 李永政, 孟煜凡, 樊知遥, 展翰翔. 胰腺神经内分泌肿瘤新辅助治疗研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 481-486.
[13] 邓小巍, 邵成浩. 胰腺神经内分泌肿瘤转化治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 456-460.
[14] 陶莹, 李晓光, 朱桃红, 杨彦, 陈琦. Westgard西格玛规则在中孕期母血清学产前筛查质量管理中的应用[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(02): 65-69.
[15] 朱芮晴, 张荣贵, 冯秀雪, 张波, 刘圣圳, 柴宁莉, 令狐恩强. 基于倾向性评分匹配法的日间消化内镜超级微创手术治疗直肠神经内分泌肿瘤的疗效评价[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(03): 166-170.
阅读次数
全文


摘要